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We would like to extend our gratitude for interest and com-
ments on our study, the results of which showed that routine 
ten-milligram fixed doses of atorvastatin are effective in about 
three quarters of type 2 diabetes mellitus (T2DM) patients for 
the treatment of hypercholesterolemia during the first 6 months 
of therapy [1].
  As noted, assessment of compliance [2] is important for drug 
evaluation and study sample size must be sufficient for statisti-
cal power. However, the retrospective nature of this study made 
it difficult to assess or guarantee compliance. We assumed that 
all patients would be equally compliant regardless of treatment 
regimen.
  Switching from atorvastatin to other statins rather than in-
creasing the dose of atorvastatin when target levels of low den-
sity lipoprotein cholesterol (LDL-C) are not reached remains 
an interesting possibility. In normal practice, increasing the 
dose is more common than switching to other statins unless 
significant side effects are observed, because atrovastatin is 
one of the most powerful statins available for reducing LDL-C 
levels [3,4].
  As to the comment regarding how to interpret poor response 
to statin therapy in patients with high body mass index (BMI). 
We found that BMI is significantly correlated with baseline 
LDL-C levels. Patients with large fat mass may harbor large 
cholesterol pools in their bodies. Thus, to reduce the levels of 
LDL-C in these patients, higher amounts of statin or combina-
tion regimens with other agents such as ezetimibe [5,6] may 
be required.
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